Navigation Links
CEL-SCI Completes $5.85 Million Registered Direct Offering
Date:6/30/2009

VIENNA, Va., June 30 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a late stage cancer immunotherapy company, today announced that it has completed a registered direct offering under which it raised gross proceeds of $5.85 million before deducting placement agent fees and estimated offering expenses. The size of the transaction, which was announced on June 24, 2009 when the Company entered into definitive agreements, was increased from $5 million. The Company sold 14,613,102 million units, with each unit consisting of one of the Company's common shares and 0.67 warrants to purchase one share of common stock. The investors purchased the units at a purchase price of $0.40 per unit. The warrants, which represent the right to acquire an aggregate of up to 9,790,777 million common shares, are exercisable at any time on or after 181 days from the Closing Date and prior to the 5-year anniversary at an exercise price of $0.50 per share. Chardan Capital Markets, LLC acted as placement agent for the offering.

The securities described above are being offered by CEL-SCI Corporation pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities may be offered only by means of a prospectus. Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the Securities and Exchange Commission's website at

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
2. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
3. CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
4. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
5. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
6. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
7. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
8. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
9. CEL-SCI Corporation Releases Letter to Shareholders
10. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
11. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... guidelines were issued today by the National Institute for Health ... Mental Health,// on the identification, treatment and management of obsessive-compulsive ... adults. , ... all ages, and commonly starts in childhood or adolescence, and ...
... calcium from food tend to gain more bone mass than ... team reports.// ,The team conducted the study to learn ... rapid-growth period of puberty in which 60 percent of the ... , ,The study, published in the November issue of ...
... of breast-feeding is associated with reduction in risk of ... studies have already provided evidence for improved insulin sensitivity ... their counterparts. ,The study is the first of ... lactation and Type 2 diabetes. More than 1,57,003 parous ...
... the life span of people who are suffering from the ... of death from cancer //and is one of the most ... cancer vaccine trial show that it improved the survival rates ... diagnosis to 88 percent." It was also found that the ...
... India has the potential to be the healthcare crisis ... billion from medical tourism, experts say.// ,Speaking at ... Industry (CII) and the Indian Health Care Foundation (IHCF), ... healthcare and facilitate public-private partnership to support quality healthcare ...
... A British grandmother from Wolverhampton has returned to the UK ... lower cost, yet another testimony to India’s burgeoning medical tourism.// ... to have the surgery on the National Health Service (NHS). ... which meant a further six months of chronic pain., ...
Cached Medicine News:Health News:Calcium From Food Better Than From Supplements 2Health News:Breastfeeding To Reduce Risk Of Type 2 Diabetes 2Health News:India Can Manage World’s Healthcare Crisis By 202 2Health News:British Grandmother has timely bypass surgery in India 2
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... NEW YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer ... the board of directors of Advaxis, Inc. ("Advaxis" or ... the board has breached its fiduciary duties to shareholders. ... published on an investing website reporting that Advaxis had ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
For canalicular laceration involving external 2/3 of one canaliculus. Medical grade silicone. Box of 3, sterile. Note: For safe and proper insertion of the punctum plug above, we recommend the use of...
For Canalicular Stenosis. Non-traumatic tip. Silicone tubing swaged into probe. Note: Tubing securely swaged into malleable stainless steel probes. Medical grade silicone. Box of 3, sterile....
For proper plug sizing....
Contour Design Eyelid Implants....
Medicine Products: